ImmunoMet Therapeutics Appoints Anthony Hörning as Head of Business Development and Licensing > Investors & Media

본문 바로가기


Investors & Media

ImmunoMet Therapeutics Appoints Anthony Hörning as Head of Business Development and Licensing

Date :
February 11, 2016

Houston, Texas, DATE February 11, 2016 – ImmunoMet Therapeutics, a 

biotechnology company developing innovative drugs for the treatment of cancer,

announced the appointment of Anthony A. Hörning as Head of Business Development &

Licensing (BD&L).  Mr. Hörning brings more than 25 years of experience in the

healthcare industry and significant expertise in international capital markets. Sung-wuk

Kim, CEO of ImmunoMet Therapeutics, said, “We are pleased to welcome Anthony to

the management team, and we look forward to his contributions. He has an outstanding

track record working with biopharmaceutical companies, and his wide-range of

experience will be valuable, as we advance our clinical development program.”  Mr.

Hörning is currently the President of Strategic Transactions Advisory AG (Basel,

Switzerland), which he founded in 2014, and he is a Senior Advisor at Vantage Partners

LLP (Boston, USA). Prior to founding his advisory company, Mr. Hörning was in charge

of the preparation, launch and ongoing implementation, as well as of all renegotiations of

global alliances as Head of Alliance Management at Novartis Pharma, where he also

created a widely recognized alliance skills training program.  He served for many years

as a member of the board of the Association of Strategic Alliance Professionals.  Prior to

his career in BD&L, Mr. Hörning was CFO of Novartis in Brazil and Head of Investor

Relations & Capital Markets for Novartis AG in Switzerland.  He gained his initial

training in international capital markets as a Vice President with JPMorgan. He earned a

Master’s Degree in Business Administration from the University of Zürich.


Copyright © ImmunoMet. All rights reserved.